Natera Unveils Multi-Modal AI Model Trained on 300,000 Patients for MRD Risk Stratification
Natera’s new multi-modal MRD risk model integrates longitudinal ctDNA, clinical data, pathology imaging and tumor sequencing using AI trained on outcomes from 300,000 Signatera patients. The company will present enhancements at an upcoming conference before launching the model in research and clinical settings.
1. Proven Leadership in Genetic Testing Platforms
Since launching its first cell-free DNA test, Panorama, in 2013, Natera has established itself as a market leader in noninvasive prenatal screening with over 50% share of the U.S. market. The company expanded its proprietary molecular and bioinformatics platform into organ health in 2017 with Prospera, a donor-derived cfDNA assay for transplant rejection monitoring, and further into oncology in 2019 with Signatera, a personalized circulating tumor DNA test for minimal residual disease and recurrence assessment. Natera’s integrated platform now serves more than 300,000 patients tested with Signatera to date and supports over 350 peer-reviewed publications, reflecting broad clinical adoption.
2. Strategic AI Collaboration with NVIDIA
In late 2023, Natera announced a multi-year partnership with NVIDIA to scale its AI foundation models across precision medicine workflows. Leveraging NVIDIA’s DGX™ SuperPOD infrastructure and CUDA-accelerated software, Natera aims to accelerate training of multimodal models that integrate longitudinal cfDNA signals, clinical phenotypes and imaging data. This collaboration underscores Natera’s commitment to high-performance computing for complex biological datasets, enabling faster model iteration and deployment of next-generation diagnostics across oncology, women’s health and organ health applications.
3. Next-Generation Multimodal MRD Risk Stratification
Natera recently unveiled advances in its Signatera MRD offering through a new multimodal risk stratification model that combines serial ctDNA measurements, digital pathology imaging and tumor sequencing data drawn from its proprietary database of 300,000+ patients. Early internal validation demonstrates statistically significant improvement in predicting recurrence risk compared to ctDNA alone. Data are slated for presentation at an upcoming oncology conference and support planned research-use and clinical launches in 2024. This innovation builds on Natera’s in-house AI initiatives, including neoantigen prediction and immuno-oncology response modeling, positioning the company to drive more personalized treatment decisions and better patient outcomes.